4170.TWO Vectorite Biomedical Inc.
- Market cap
- TWD 481M
- P/E
- 4.1x
- P/B
- 0.98x
- ROE
- 19.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4170.TWO undervalued?
Graham number4170.TWO trades 57.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vectorite Biomedical Inc. fundamental analysis
No fundamental analysis for Vectorite Biomedical Inc. yet.
Vectorite Biomedical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vectorite Biomedical Inc.
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. The company is involved in cell preparation product manufacturing; and collection and storage of immune cells. Its products are used in the field of infectious diseases and inflammation, cancer, and oncology. The company was incorporated in 2004 and is based in New Taipei City, Taiwan.
Full company profileVectorite Biomedical Inc. financial statements
Vectorite Biomedical Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 26.5M | 24.5M | 28.8M | 42.9M | 55.9M | 57.8M | 61.4M |
| Gross Profit | 2.83M | 1.92M | -2.47M | 707K | 16.4M | 17.0M | 21.7M |
| Operating Income | -99.6M | -60.9M | -42.4M | 30.5M | -16.1M | -26.0M | -21.9M |
| EBITDA | -80.0M | -42.7M | -25.9M | -21.7M | -6.97M | -17.2M | 104M |
| Net Income | -90.3M | -68.2M | 8.36M | -26.4M | -6.60M | -40.1M | 96.2M |
| EPS | -2.14 | -2.33 | 0.23 | -0.60 | -0.15 | -0.92 | 2.20 |
| Balance Sheet | |||||||
| Total Assets | 389M | 369M | 493M | 466M | 452M | 413M | 510M |
| Total Liabilities | 48.9M | 24.0M | 25.7M | 24.5M | 21.3M | 23.2M | 24.5M |
| Shareholders' Equity | 286M | 345M | 467M | 441M | 430M | 389M | 485M |
| Cash & Short-term Investments | 115M | 89.6M | 239M | 214M | 204M | 185M | 25.7M |
| Total Debt | 20.3M | - | - | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -62.7M | -36.9M | -65.8M | 14.7M | 1.30M | -11.5M | -5.79M |
| Capital Expenditure | 4.31M | 771K | 1.80M | 888K | 4.76M | 2.84M | 4.00M |
| Free Cash Flow | -67.0M | -37.7M | -67.6M | 13.8M | -3.46M | -14.4M | -9.78M |
| Ratios | |||||||
| ROE | -31.6% | -19.8% | 1.8% | -6.0% | -1.5% | -10.3% | 19.8% |
| ROA | -23.2% | -18.5% | 1.7% | -5.7% | -1.5% | -9.7% | 18.9% |
| Net Profit Margin | -340.1% | -277.8% | 29.1% | -61.5% | -11.8% | -69.3% | 156.6% |
| Debt to Equity | 0.07x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vectorite Biomedical Inc. dividends
Vectorite Biomedical Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1100.566:1000 on Aug 27, 2015.
Who owns Vectorite Biomedical Inc.
Ownership data of Vectorite Biomedical Inc. is not available yet.
Vectorite Biomedical Inc. company profile
- Company name
- Vectorite Biomedical Inc.
- Ticker
- 4170.TWO
- ISIN
- TW0004170006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 97, Xintai 5th Road, New Taipei City, Taiwan, 22175
- Phone
- 886 2 2697 1100
- Website
- vectorite.com.tw
About Vectorite Biomedical Inc.
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. The company is involved in cell preparation product manufacturing; and collection and storage of immune cells. Its products are used in the field of infectious diseases and inflammation, cancer, and oncology. The company was incorporated in 2004 and is based in New Taipei City, Taiwan.
Vectorite Biomedical Inc. management
2- Kechang OuGeneral Manager
- Hui Jing YouAccounting Supervisor